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Myeloid-derived interleukin-1β drives oncogenic
KRAS-NF-κΒ addiction in malignant pleural effusion
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Malignant pleural effusion (MPE) is a frequent metastatic manifestation of human cancers.
While we previously identiﬁed KRAS mutations as molecular culprits of MPE formation, the
underlying mechanism remained unknown. Here, we determine that non-canonical IKKα-RelB
pathway activation of KRAS-mutant tumor cells mediates MPE development and this is fueled
by host-provided interleukin IL-1β. Indeed, IKKα is required for the MPE-competence of KRAS-
mutant tumor cells by activating non-canonical NF-κB signaling. IL-1β fuels addiction of
mutant KRAS to IKKα resulting in increased CXCL1 secretion that fosters MPE-associated
inﬂammation. Importantly, IL-1β-mediated NF-κB induction in KRAS-mutant tumor cells, as
well as their resulting MPE-competence, can only be blocked by co-inhibition of both KRAS
and IKKα, a strategy that overcomes drug resistance to individual treatments. Hence we show
that mutant KRAS facilitates IKKα-mediated responsiveness of tumor cells to host IL-1β,
thereby establishing a host-to-tumor signaling circuit that culminates in inﬂammatory MPE
development and drug resistance.
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Malignant pleural effusion (MPE) is one of the mostchallenging cancer-related disorders. It ranks amongthe top prevalent metastatic manifestations of tumors of
the lungs, breast, pleura, gastrointestinal tract, urogenital tract,
and hematopoietic tissues, killing an estimated two million
patients worldwide every year and causing 126,825 admissions in
U.S. hospitals in 2012 alone1,2. The presence of a MPE at diag-
nosis is an independent negative prognostic factor in patients
with lung cancer and mesothelioma3,4. In addition, current
therapies are non-etiologic and often ineffective, may cause fur-
ther morbidity and mortality, and have not yielded signiﬁcant
improvements in survival5,6.
To meet the pressing need for mechanistic insights into the
pathobiology of MPE, we developed immunocompetent mouse
models of the condition that unveiled inﬂammatory tumor-to-
host signaling networks causing active plasma extravasation into
the pleural space7. Nuclear factor (NF)-κB activity in tumor cells
was pivotal for MPE formation in preclinical models, driving pro-
inﬂammatory gene expression and promoting pleural tumor cell
survival8–10. However, the mechanism of oncogenic NF-κB acti-
vation of MPE-competent pleural tumor cells remained
unknown. In parallel, we recently pinned mutant KRAS as a
molecular determinant of the propensity of pleural-metastasized
tumor cells for MPE formation: mutant KRAS delivered its pro-
MPE effects by directly promoting C-C chemokine motif ligand 2
(CCL2) secretion by pleural tumor cells, resulting in pleural
accumulation of MPE-fostering myeloid cells11. However, a
unifying mechanism linking KRASmutations with oncogenic NF-
κB activation and MPE competence of pleural tumor cells was
missing.
KRAS mutations have been previously linked to elevated or
aberrant NF-κB activity via cell-autonomous and paracrine
mechanisms. KRAS-mutant tumors, including lung and pan-
creatic adenocarcinomas, require active NF-κB signaling12–14 and
NF-κB inhibition blocks KRAS-induced tumor growth14–16. In
turn, NF-κB activation of KRAS-mutant tumor cells has been
associated with enhanced RAS signaling, drug resistance, and
stemness17,18. Despite signiﬁcant research efforts, the NF-κB-
activating kinases (ΙκΒ kinases, IKK) and pathways (canonical,
involving ΙκΒα, ΙΚΚβ, and RelA/P50, versus non-canonical,
comprising IκΒβ, ΙΚΚα, and RelB/P52) that mediate this onco-
genic addiction between mutant KRAS and NF-κB signaling are
still elusive and diverse, and different studies indicate that IKKα,
IKKβ, IKKγ, IKKε, and/or TANK-binding kinase 1 (TBK1) are
key for this17–24.
Here we use immunocompetent mouse models of MPE to
show that mutant KRAS determines the responsiveness of pleural
tumor cells to host-delivered interleukin (IL)-1β signals by
directly regulating IL-1 receptor 1 (IL1R1) expression. IKKα is
further shown to critically mediate IL-1β signaling in KRAS-
mutant tumor cells, culminating in marked MPE-promoting
effects delivered by C-X-C chemokine motif ligand 1 (CXCL1),
and in oncogenic addiction with mutant KRAS evident as drug
resistance. Importantly, simultaneous inhibition of IKKα and
KRAS is effective in annihilating mutant KRAS-IKKα addiction in
MPE.
Results
Non-canonical NF-κB signaling of KRAS-mutant cancer cells.
We ﬁrst evaluated resting-state NF-κB activity of ﬁve mouse
cancer cell lines with deﬁned KRAS mutations and MPE cap-
abilities in syngeneic C57BL/6 mice11: Lewis lung carcinoma
(LLC; MPE-competent; KrasG12C), MC38 colon adenocarcinoma
(MPE-competent; KrasG13R), AE17 malignant pleural mesothe-
lioma (MPE-competent; KrasG12C), B16F10 skin melanoma, and
PANO2 pancreatic adenocarcinoma (both MPE-incompetent and
KrasWT) cells. Parallel transient transfection of these cell lines
with reporter plasmids encoding Photinus Pyralis LUC under
control of either a constitutive (pCAG.LUC) or a NF-κB-
dependent (pNF-κB.GFP.LUC; pNGL) promoter8–11,25 (Fig. 1a)
revealed that unstimulated NF-κB activity did not segregate by
KRAS mutation status (Fig. 1b). However, when PANO2 cells, a
cell line with relatively low NF-κB activity, were transiently
transfected with pKrasG12C, their NF-κΒ expression levels were
elevated (Fig. 1c). Moreover, KRAS mutant (MUT) cells displayed
elevated DNA-binding activity of non-canonical NF-κB subunits
P52 and RelB by functional NF-κΒ enzyme-linked immunosor-
bent assay (ELISA) and enhanced nuclear immunoﬂuorescent
localization of RelB compared with KRASWT cells (Fig. 1d, e).
Immunoblotting of cytoplasmic and nuclear extracts revealed that
KRASMUT cells had increased levels of cytoplasmic RelA and
IκΒα and of nuclear RelB, ΙκΒβ, and ΙΚΚα compared with
KrasWT cells (Fig. 1f). These results suggest that KRASMUT cancer
cells exhibit non-canonical endogenous NF-κB activity.
Resistance of KRAS-mutant cancer cells to IKKβ inhibition.
We next examined the effects of small molecule inhibitors of the
proteasome (bortezomib26), of IKKβ (IMD-035427), or of heat
shock protein 90 (HSP90) (17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG)28) that display signiﬁcant
inhibitory activity against IKKβ and/or IKKα (of note, a speciﬁc
IKKα inhibitor does not exist) on NF-κB reporter activity and
cellular proliferation of our murine cancer cell lines (Fig. 1g, h;
Supplementary Table 1). Bortezomib, an indirect inhibitor of
IKKβ via cytoplasmic accumulation of non-degraded ΙκΒα16,26,
attenuated endogenous NF-κB activity of KrasWT cells but
paradoxically activated NF-κB in KRASMUT cells, at the same
time more effectively killing KRASWT than KRASMUT cells
in vitro. Similarly, IKKβ-selective IMD-035427 blocked NF-κB
activity and cellular proliferation of unstimulated KRASWT cells
but not of KRASMUT cells. Interestingly, the HSP90 and dual
IKKα/IKKβ inhibitor 17-DMAG29 was equally effective in lim-
iting NF-κB activity and cellular proliferation of all cell lines
irrespective of KRAS mutation status. These results suggest the
existence of endogenous resistance of KRAS-mutant cells to IKKβ
inhibition, which can be overcome by combined HSP90/IKKα/
IKKβ inhibition.
IL-1-inducible NF-κB activation of KRAS-mutant cancer cells.
We next studied NF-κB activation patterns of our murine cancer
cells in response to exogenous stimuli. For this, cells were stably
transfected with pNGL, were pretreated with saline or bortezomib
(1 μM ~5–10-fold the 50% NF-κB inhibitory concentration
obtained from KrasWT cells; Supplementary Table 1), were
exposed to 60 different candidate NF-κB-pathway ligands at 1 nM
concentration30, and were longitudinally monitored for NF-κB-
dependent LUC activity by bioluminescence imaging of live cells
in vitro (Fig. 2a, b; Supplementary Table 2). Incubation with
lipopolysaccharide (LPS) and tumor necrosis factor (TNF)
resulted in markedly increased NF-κB activity in all cells irre-
spective of KRAS status, while lymphotoxin β activated NF-κB in
all but PANO2 cells, effects that peaked by 4–8 h of incubation
and subsided by 16–24 h. Uniquely, IL-1α and IL-β induced NF-
κB exclusively in KRASMUT cells. In addition, bortezomib exag-
gerated endogenous and inducible NF-κB activation of KRASMUT
cells, in contrast to KRASWT cells that displayed efﬁcient NF-κΒ
blockade by bortezomib. In line with the above, Il1r1 (encoding
IL1R1, cognate to IL-1α/β) expression, but not Tnfrsf1a/Tnfrsf1b
(encoding TNF receptors) or Il1a/Il1b expression (that was
undetectable in all cell lines), was exclusively restricted to
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KRASMUT MPE-proﬁcient tumor cells (Fig. 2c, d). We subse-
quently tested whether inducible NF-κB activation occurs in
tumor cells entering the pleural space in vivo, simulating incipient
pleural carcinomatosis4,7. For this, naive C57BL/6 mice were
pulsed with a million intrapleural pNGL-expressing tumor cells
and were serially imaged for NF-κB-dependent bioluminescence.
Amazingly, KRASMUT MPE-competent cells responded to the
pleural environment with markedly escalated NF-κB activity
within 4 h after injection, while KRASWT MPE-incompetent cells
showed diminishing NF-κB signals (Fig. 3a). Interestingly, this
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in vivo NF-κB response of KRASMUT cells was abolished in IL-
1β-deﬁcient (Il1b−/−31), but not in TNF-deﬁcient (Tnf−/−32),
mice (Fig. 3b), indicating that KRASMUT tumor cells selectively
respond to IL-1β of the pleural environment by activating NF-κB.
Mutant KRAS promotes non-canonical NF-κB signaling. To
deﬁne the role of mutant KRAS in the aberrant NF-κB activation
patterns of KRASMUT tumor cells, including non-canonical
endogenous NF-κB activity, resistance to IKKβ inhibition, and
IL-1β-inducibility, we undertook short hairpin RNA (shRNA)-
mediated KRAS silencing (shKras) and plasmid-mediated over-
expression of a mutant dominant-negative form of ΙκΒα (pΙκ-
ΒαDN; inhibits canonical NF-κΒ signaling) in KRASMUT cell
lines, as well as plasmid-mediated overexpression of mutant
KRAS (pKrasG12C) in KRASWT cell lines11,33. Stable pΙκΒαDN
expression in MC38 cells (KrasG13R) resulted in decreased RelA
and sustained RelB nuclear-binding activity, while shKras did not
affect RelA but abolished RelB nuclear-binding activity (Fig. 4a).
shKras also eliminated nuclear RelB localization in these cells
without affecting RelA (Fig. 4b) and abolished nuclear IKKα
immunoreactivity of LLC (KrasG12C) and MC38 cells (Fig. 4c).
shKras expression reversed the endogenous resistance of MC38
cells to bortezomib and IMD-0354, rendering them as sensitive as
KRASWT cells (Fig. 4d, e). In addition, shKras annihilated IL-1β-
induced NF-κB transcriptional activity of pNGL-expressing LLC,
MC38, and AE17 (KrasG12C) cells (Fig. 4f), and pKrasG12C
transmitted this phenotype to KrasWT PANO2 cells (Fig. 4g).
Importantly, shKras abrogated the in vivo NF-κB response of
pleural-inoculated MC38 cells, which was reinstated in PANO2
cells by stable pKrasG12C expression (Fig. 4h, i). In parallel, KRAS
silencing in KRASMUT cells signiﬁcantly decreased, whereas
pKrasG12C overexpression in KRASWT cells signiﬁcantly
increased Il1r1 expression, as well as resting-state and IL-1β-
inducible nuclear immunoreactivity for RelB, IκΒβ, and ΙΚΚα
(Fig. 4j–l). Collectively, these data indicate that mutant KRAS
induces non-canonical NF-κΒ signaling of cancer cells in unsti-
mulated and IL-1β-stimulated conditions.
IKKα in mutant KRAS-dependent MPE. To deﬁne the NF-κB-
activating kinase responsible for aberrant NF-κΒ signaling of
KRASMUT cancer cells, we stably expressed shRNAs speciﬁcally
targeting IKKα, IKKβ, IKKε, and TBK1 transcripts (Chuk, Ikbkb,
Ikbke, and Tbk1, respectively) in our pNGL-expressing cell lines
and validated them (Fig. 5a). In addition, we cloned these murine
transcripts into an eukaryotic expression vector and generated
stable transfectants of our cell lines. Interestingly, resting-state
NF-κB transcriptional activity across KRASMUT cells was mark-
edly suppressed by shChuk but not by shIkbkb or shTbk1, while
shIkbke yielded minor NF-κΒ inhibition in MC38 and AE17 cells.
On the contrary, endogenous NF-κΒ-mediated transcription of
B16F10 cells was exclusively silenced by shIkbkb and, to a lesser
extent, shIkbke, and of PANO2 cells by no shRNA (Fig. 5b). In a
reverse approach, overexpression of any kinase resulted in
enhanced NF-κΒ activity in all KRASMUT cells, of IKKβ only in
B16F10 cells, and of no kinase in PANO2 cells (Fig. 5c). In
addition to intrinsic, IKKα also mediated IL-1β-inducible NF-κΒ
activity of KRASMUT tumor cells, since shChuk but not shIkbkb
abolished IL-1β-induced NF-κB activity across KRASMUT cell
lines (Fig. 5d). In line with the above, shChuk abolished the
immunoreactivity of MC38 cell nuclear extracts for RelB, ΙκΒβ,
and IKKα, both at resting and IL-1β-stimulated states (Fig. 5e).
Taken together, these data suggest that KRAS-mutant cancer cells
respond to pleural IL-1β via IKKα-mediated non-canonical NF-
κB activation. Based on these results and our previous identiﬁ-
cation of the importance of KRASmutations and NF-κΒ signaling
in MPE development8–11, we hypothesized that IKKα is required
for sustained NF-κΒ activation and MPE induction by pleural-
homed KRASMUT cancer cells. To test this, we injected IKK-
silenced pNGL-expressing LLC cells (KrasG12C; MPE-competent)
into the pleural space of C57BL/6 mice. Indeed, recipients of
IKKα-silenced LLC cells displayed signiﬁcant reductions in MPE
incidence and volume, pleural inﬂammatory cell inﬂux, and
pleural tumor NF-κΒ activity and prolonged survival. IKKε
silencing delivered more modest and equivocal beneﬁcial effects,
while IKKβ and TBK1 silencing had no impact (Fig. 6a–c; Sup-
plementary Table 3). These experiments were repeated with
IKKα- and IKKβ-silenced MC38 cells (KrasG13R; MPE-compe-
tent) stably expressing pNGL, conﬁrming that IKKα is cardinal
for oncogenic NF-κΒ activation and MPE precipitation by
pleural-metastatic KRASMUT tumor cells (Fig. 6d–f; Supplemen-
tary Table 3). However, standalone overexpression of IKKα or
IKKβ did not confer MPE competence to KRASWT PANO2 cells,
as opposed to pKrasG12C (Fig. 6g–i; Supplementary Table 3), in
accord with our previous observations11. Collectively, these
results suggest that mutant KRAS-potentiated IL-1β signaling
results in KRASMUT addiction to IKKα activity, which is required
but not sufﬁcient for oncogenic NF-κΒ activation and MPE
formation.
Myeloid IL-1β fosters mutant KRAS-IKKα addiction in MPE.
To study the importance of host-delivered IL-1β in the proposed
KRASMUT-IKKα addiction culminating in MPE, we delivered
pNGL-expressing KRASMUT LLC and MC38 cells into the pleural
space of Il1b−/−, Tnf−/−, and WT C57BL/6 mice. Interestingly,
Il1b−/− but not Tnf−/− mice displayed decreased MPE inci-
dence, volume, inﬂammatory cell inﬂux, and oncogenic NF-κB
Fig. 1 Kras-mutant tumor cells exhibit non-canonical endogenous NF-κΒ activity. Five different C57BL/6 mouse tumor cell lines with (KrasMUT: LLC, MC38,
AE17) or without (KrasWT: B16F10, PANO2) Kras mutations were assessed for activation and inhibition of resting NF-κΒ activity in vitro. a Map of NF-κΒ
reporter plasmid (NF-κΒ.GFP.Luc; pNGL). Partial pNGL sequence at origin (1) showing κΒ-binding motifs (red) and GFP sequence (green). b Representative
image and data summary (n= 3) of area under curve of cumulative bioluminescence emitted by cells transiently transfected with reporter plasmids pCAG.
LUC or pNGL. c Data summary (n= 8) of bioluminescence emitted by PANO2 cells stably expressing pNGL reporter plasmid at 48 h after transient
transfection with pC or pKrasG12C. d Data summary (n= 5) of DNA NF-κB motif binding activity of nuclear extracts by NF-κB ELISA relative to nuclear
extracts of Raji leukemia cells. e Immunoﬂuorescent detection of RelA and RelB in cells grown on glass slides (n= 3) showing increased nuclear localization
of RelB in KrasMUT cells and of RelA in KrasWT cells (arrows). f Immunoblots of cytoplasmic and nuclear extracts for NF-κB pathway members and β-actin
(representative of n= 3 independent experiments). Data presented as mean± s.d. P, overall probability by one-way (b) and two-way (d) ANOVA or
Student’s t-test (c). *P< 0.05 and ***P< 0.001 for the indicated comparisons by Bonferroni post-tests. g Data summary (n= 3) of pNGL reporter activity
after 4-h treatment and of cell proliferation by MTT assay after 72-h treatment in response to bortezomib, IMD-0354, or 17-DMAG. Data presented as
mean± s.d. from n= 3 replicates/data point. P, probability of no difference between cell lines by extra sum-of-squares F test. h, i Data summary of 50%
inhibitory concentrations (IC50) of NF-κΒ activity (by pNGL reporter activity) and cell proliferation (by MTT; g). Data presented as mean± s.d. from n= 3
independent experiments. P, probability of no difference by two-way ANOVA. ns and triple asterisks (***): P> 0.05 and P< 0.001, respectively, for the
indicated comparisons by Bonferroni post-tests. nd not determined
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activation (Fig. 7a–d; Supplementary Table 3). Host-provided IL-
1β was of myeloid origin, since bone marrow (BM) trans-
plants34,35 from C57BL/6 and Tnf−/−, but not Il1b−/− donors, to
lethally irradiated Il1b−/− recipients unable to foster MPE ren-
dered LLC cells MPE proﬁcient (Fig. 7e, f; Supplementary
Table 3). To deﬁne which myeloid cells provide the bulk of IL-1β
to fuel tumor cell NF-κΒ activity, we isolated BM cells from
C57BL/6 mice and drove them toward monocyte and neutrophil
differentiation by macrophage colony-stimulating factor (M-CSF)
and granulocyte-colony-stimulating factor (G-CSF culture,
respectively. Both BM-derived monocytes and neutrophils
secreted IL-1β upon 24-hour treatment with cell-free LLC
supernatants as measured by ELISA, but monocytes secreted
~200 times higher cytokine levels than undifferentiated BM cells
0
1
2
3
0 20 40 60
0
1
2
3
0
2
4
6
0 20 40 60
0
2
4
6
0
4
8
0 20 40 60
0
4
8
0
20
40
0 20 40 60
0
20
40
0
5
10
0 20 40 60
0
5
10
Hours on treatment
PBS
LPS
TNF
LTβ
IL-1β
***
***
***
***
***
***
***
ns
***
ns
a B16F10 (WT)MC38 (G13R)LLC (G12C) AE17(G12C) PANO2 (WT)
Luminescence
1.0
0.8
0.6
0.4
×105
0.2
0.0
Color scale
Min = –1.00e4
Max = 1.00e5
Radiance
(p/sec/cm2/sr)
Saline
PBS
LPS
TNF
LT-β
CCL2
SPP1
IL-1β
IL-5
Bortezomib
H
ou
rs
 o
n 
tr
ea
tm
en
t
0
4
8
b B16F10 (WT)MC38 (G13R)LLC (G12C) AE17 (G12C) PANO2 (WT)
B
.L
uc
 (x
 b
as
el
in
e)
S
aline
B
ortezom
ib
0
1
2
3
*
0
1
2
3
0
1000
2000
3000
0
100
200
300
0
1
** *
* *
*
**
*
**
*
**
*
**
*
**
*
2
m
R
N
A
(2
–Δ
C
t  g
en
e/
G
us
b)
(x 
B
16
F
10
)
d
Tnfrsf1a Il1r1Tnfrsf1b
P < 0.0001 P < 0.0001
ns
c n
s
ns
ns
c
P < 0.0001
c n
s
P = 0.0001
ns ns ns c
P = 0.0007
ns
ns
ns
c
Tnfrsf1a Tnfrsf1b Il1r1 Il1a Il1b
0
100
200
300 LLC
MC38
AE17
B16F10
PANO2
m
R
N
A
(g
en
e/
G
us
b)
(x
 B
16
F
10
)
c P = 0.0035
Il1a Il1b
Fig. 2 Kras-mutant tumor cells possess IL-1β-inducible NF-κΒ activity. Five different C57BL/6 mouse tumor cell lines with (LLC, MC38, AE17) or without
(B16F10, PANO2) Kras mutations were assessed for inducible NF-κΒ activation in response to exogenous stimuli and for the expression of relevant
receptors in vitro. a, b Representative bioluminescent images (a; shown are n= 3 replicates/data-point) and data summary (b; mean± s.d. of n= 3
independent experiments) of cells stably expressing pNGL and pretreated with saline or 1 μM bortezomib at different time points after addition of 1 nM of
the indicated NF-κΒ ligands (arrows in a and legend in b). Note NF-κB inducibility by IL-1β and bortezomib exclusively in KrasMUT cells. ns and *** P> 0.05
and P< 0.001, respectively, for comparison between ligands indicated by colored arrows and PBS at 4 and 8 h on treatment by two-way ANOVA with
Bonferroni post-tests. c, d Tnfrsf1a, Tnfrsf1b, Il1r1, Il1a, and Il1b mRNA expression relative to Gusb by microarray (c) and qPCR (d). Shown are mean (c) and
mean± s.d. (d) of n= 5 independent technical replicates of one biologic sample. P, probability of no difference between cell lines by two-way (c) or one-
way (d) ANOVA. ns, single, double, and triple asterisks (*, **, and ***): P> 0.05, P< 0.05, P< 0.01, and P< 0.001, respectively, for comparison with
B16F10 cells (c) by Bonferroni post-tests
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and neutrophils (Fig. 7g). These data clearly show that the main
source of IL-1β in the pleural space during MPE development
likely are recruited myeloid monocyte cells.
Mutant KRAS-IKKα addiction promotes MPE via
CXCL1 secretion. To identify the MPE effectors and transcrip-
tional signatures of IL-1β/KRAS/IKKα-addicted tumor cells, we
subjected KRAS-silenced, IKKα-silenced, and IL-1β-challenged
LLC and MC38 cells to microarray analyses, seeking for tran-
scripts altered heterodirectionally by silencing/challenge. Thirty
transcripts fulﬁlled these criteria in LLC (including Ppbp,
encoding pro-platelet basic protein, PPBP, and Cxcl1, encoding
CXCL1) and 20 in MC38 (including Cxcl1) cells, with Cxcl1 being
the only common gene of these two signatures (Fig. 8a, b; Sup-
plementary Tables 4, 5). Cxcl1 microarray results were validated
by quantitative PCR (qPCR) and ELISA (Fig. 8c–e). Furthermore,
chromatin immunoprecipitation (ChIP) was performed in LLC
cells treated with phosphate-buffered saline (PBS) or IL-1β in
order to specify whether and which NF-κB component directly
binds to the promoter region of Cxcl1. The data indicate that only
RelB and IKKα bind to the NF-κB element in the Cxcl1 promoter
and that IL-1β signiﬁcantly strengthens this binding (Fig. 8f).
These ﬁndings are consistent with the enhanced transcriptional
induction of Cxcl1. Moreover, Cxcl1 and Ppbp expression was
pivotal for MPE induction by IL-1β/KRAS/IKKα-addicted LLC
cells, since these were MPE incompetent in both C-X-C chemo-
kine motif receptor 1 (CXCR1) and CXCR2 gene-deﬁcient
mice36,37 that lack the genes encoding CXCL1/PPBP-cognate
CXCR1 and CXCR2 receptors38 (Fig. 8g; Supplementary Table 3).
Notably, in MPEs from CXCR1 and CXCR2 gene-deﬁcient mice
the predominant cell population was monocytes, whereas in
MPEs from CCR2 gene-deﬁcient mice11 the prevalent cell type
was neutrophils. This result was not unexpected since the
majority of myeloid cells recruited in the pleural space during
MPE development in C57BL/6 mice consist of both neutrophils
and monocytes (Fig. 8h). Of note, the monocyte population is the
most prevalent during MPE development.
Combined targeting of KRAS/IKKα is effective against MPE.
To explore the therapeutic implications of the proposed
mechanism, we examined potential synergy of the KRAS inhi-
bitor deltarasin39 with the IKKβ-speciﬁc inhibitor IMD-0354 or
the HSP90/IKKα/IKKβ inhibitor 17-DMAG using TNF- or IL-
1β-stimulated LLC murine and A549 human lung adenocarci-
noma cells expressing pNGL (Fig. 9a, b). Interestingly, all inhi-
bitors alone or in combination failed to block TNF-inducible NF-
κΒ activation in both cell lines. In addition, all standalone drugs
failed to inhibit IL-1β-inducible NF-κΒ activation in both cell
lines, except from partial effects observed in A549 cells by 17-
DMAG. However, deltarasin/17-DMAG but not deltrarasin/
IMD-0354 combination treatment completely abolished IL-1β-
induced NF-κB activation in both cell types to unstimulated levels
(Fig. 9a, b), indicating that drugging the KRAS/IKKα axis can halt
IL-1β responsiveness. To determine the potential efﬁcacy of this
approach against MPE, standalone or combined deltarasin, and
17-DMAG treatments (both 15 mg/Kg) were delivered to mice
with established pleural tumors. For this, C57BL/6 mice received
pleural LLC cells and treatments commenced after 5 days to allow
initial pleural tumor implantation11. At day 13 post-tumor cells,
standalone deltarasin and 17-DMAG-treated mice had sig-
niﬁcantly decreased MPE volume compared with saline-treated
controls (40% reductions for both groups; P< 0.05; one-way
analysis of variance (ANOVA) with Bonferroni post-tests).
However, combination-treated mice were markedly protected
from MPE development (57% incidence) and progression (65%
volume reduction; P< 0.001; one-way ANOVA with Bonferroni
post-tests) (Fig. 9c; Supplementary Table 3). Hence combined
targeting of mutant KRAS and IKKα is effective in halting
oncogenic NF-κΒ activation and MPE in mice.
IL-1β-inducible NF-κΒ activity in human KRAS-mutant cells.
To assess whether our ﬁndings are relevant to human cancer, we
screened nine human cancer cell lines of known KRAS mutation
status40 for Rel-binding activity of nuclear extracts. In accord with
murine data, KRASMUT cells displayed enhanced nuclear RelB
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compared with RelA binding (Fig. 10a). In addition, A549
(KRASG12S) and NCI-H23 (KRASG12C) cells displayed IL-1β-
induced NF-κΒ activation, as opposed to HT-29 and SKMEL2
cells (both KRASWT). Importantly, stable pKrasG12C expression
in SKMEL2 cells rendered them responsive to IL-1β (Fig. 10b, c).
In summary, KRAS mutations alter NF-κΒ signaling in tumor
cells. KRASWT cells preferentially utilize intrinsically or exogen-
ously (i.e., by LPS, TNF) stimulated IKKβ-mediated NF-κΒ
signaling, display sensitivity to IKKβ inhibition, poor CXCR1/2
ligand secretion, and MPE incompetence. KRASMUT cells
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predominantly use IKKα-mediated non-canonical NF-κΒ signal-
ing at resting state and in response to myeloid IL-1β, display
enhanced CXCR1/2 ligand secretion and MPE proﬁciency, and
are addicted to sustained IKKα activity evident as resistance to
IKKβ inhibitors.
Discussion
We provide a novel paradigm of how an oncogene can co-opt the
host environment to foster addiction with a perturbed signaling
pathway. KRAS-mutant cancer cells are shown to respond to host
provided IL-1β in the pleural space by increasing non-canonical
IKKα-RelB pathway activity. The co-existence of mutant KRAS
and elevated IKKα-mediated non-canonical NF-κB signaling in
the cancer cell, relentlessly driven by host IL-1β, leads to two
important consequences. First, to enhanced transcription of
CXCL1/PPBP chemokines, recruitment of CXCR1+ and CXCR2+
myeloid cells, and frank escalation of inﬂammatory MPE devel-
opment. Second, to oncogenic addiction between mutant KRAS
and IKKα that culminates in drug resistance. Using immuno-
competent mouse models of MPE, we show how IL-1β, mutant
KRAS, and IKKα interplay to mediate non-canonical NF-κB
activation, resistance to proteasome and IKKβ inhibitors, CXCL1/
PPBP secretion, and MPE. Finally, we show that this partnership
can be annihilated by combined inhibition of KRAS together with
IKKα but not alone.
Although cell-autonomous pro-tumorigenic functions of
mutant KRAS are well charted41–43, mechanisms utilized by the
oncogene to co-opt host cells from the tumor microenvironment
in order to favor tumor progression have only recently begun to
be elucidated. In this regard, mutant KRAS was ﬁrst shown to
promote chemokine secretion by tumor-initiated cells, thereby
promoting tumor-associated inﬂammation44,45. Along similar
lines, we recently showed that the oncogene is responsible for
CCL2 secretion by pleural metastatic cancer cells, fostering
inﬂammatory MPE formation11. Our present ﬁndings expand the
paradigm of how mutant KRAS impacts tumor–host interactions:
it renders tumor cells capable of sensing inﬂammatory IL-1β
signals originating from the CCL2-recruited monocytes. The
increased Il1r1 expression in these cells could be a result of IL-1β
-induced phosphorylation by nuclear IKKa of Ser10 in histone H3
that could be especially important for subsequent modiﬁcations
in a variety of genes, including Il1r1. Moreover, integrated by
IKKα-mediated non-canonical NF-κΒ activity, IL-1β signaling
culminates in enhanced CXCL1/PPBP expression and secretion
that function to escalate tumor-associated inﬂammation required
for MPE. Hence, in addition to directly promoting chemokine
expression, mutant KRAS is shown here to amplify host-
originated inﬂammatory signals in order to escalate MPE-
promoting inﬂammation.
Mutant KRAS is known to enhance oncogenic NF-κB activity;
however, it was mainly linked to IKKβ, ΙΚΚε, and TBK1 func-
tion12,14,17,18,21,23,24,43, and only two studies identiﬁed IKKα as
an accessory to IKKβ in KRAS-mutant lung adenocarcinoma22
and epidermal growth factor receptor-driven head and neck
cancers19. Here we show for the ﬁrst time that KRAS-mutant
cancer cells display altered NF-κΒ utilization in resting and sti-
mulated states, a phenomenon previously identiﬁed in pancreatic
β cells46. Indeed, KRAS-mutant cancer cells displayed non-
canonical endogenous NF-κΒ activity evident by enhanced
nuclear localization and/or DNA-binding activity of RelB, ΙκΒβ,
and ΙΚΚα, which was further inducible by exogenous IL-1β.
Importantly, non-canonical NF-κΒ utilization by KRAS-mutant
cancer cells was IKΚα driven, involved RelB activation, and was
required for MPE. Nuclear IKΚα functions have been identiﬁed
previously, including histone 3 modiﬁcations augmenting TNF
and receptor activator of NF-κB ligand-induced gene expression
and repression of maspin, a metastasis gate-keeper47–49. Our
work links IKKα function with IL-1β-induced RelB activation and
CXCL1/PPBP transcription. Moreover, we provide novel evi-
dence that mutant KRAS is indirectly responsible for non-
canonical NF-κB activation, which is IKKa and RelB based, via
sensitization of cancer cells to host IL-1β. Finally, IKKα is found
to be responsible for MPE, an important metastatic manifestation
of various cancers. The ﬁndings concur with previous reports of a
combined requirement for IKKα and IKKβ for oncogenic NF-κB
activation19,22, as well as with human observations of pre-
dominant non-canonical NF-κB activity of tumors with high
incidence of KRAS mutations, such as lung adenocarcinoma50.
However, we demonstrate an isolated requirement for IKKα in
KRAS-driven MPE, an important cancer phenotype.
In recent years, inﬂammation was established as a conditional
tumor promoter51. IL-1α/β are important components of the
tumor microenvironment that stimulate tumor invasiveness and
angiogenesis52. Myeloid-derived IL-1β is implicated in the resis-
tance to NF-κΒ inhibitors and IL-1β antagonism yielded bene-
ﬁcial effects in a mouse model of KRAS-mutant pancreatic
cancer53,54. We found previously that IL-1α/β are present in
human and experimental MPE and that MPE-competent ade-
nocarcinomas trigger myeloid cells to secrete IL-1β35. Here the
mechanism of pleural IL-1β function in MPE promotion is elu-
cidated: CCL2-attracted monocyte-released IL-1β fosters NF-κΒ
activation of MPE-prone KRAS-mutant carcinomas by poten-
tiating non-canonical NF-κB signaling via IKKα. Undoubtedly,
IL-1β is not the sole NF-κΒ ligand expressed in the malignancy-
affected pleural space: TNF, a known stimulator of canonical NF-
κB signaling, is present in MPE and promotes disease progres-
sion9. However, TNF likely originates from tumor cells in MPE9
and non-speciﬁcally triggers NF-κB activation in any tumor type
irrespective of its KRAS status and MPE competence, suggesting
Fig. 4 Mutant Kras drives basal and IL-1β-induced non-canonical NF-κB signaling and drug resistance. a RelA and RelB binding of nuclear extracts of MC38
cells stably expressing a control plasmid (pC), a mutant dominant-negative form of ΙκΒα (pΙκΒαDN), control shRNA (shC), or anti-Kras shRNA (shKras)
relative to Raji leukemia cells by NF-κB ELISA (n= 3 experiments). b Immunoﬂuorescent detection of RelA and RelB in MC38 cells showing increased
nuclear RelB (arrows) and its disappearance in cells expressing shKras. c IKKα immunoblots of cytoplasmic and nuclear extracts of LLC and MC38 cells
expressing shC or shKras. (n= 3 experiments). d, e MTT data (n= 3 replicates/data-point) and mean (95% CI) IC50 values (n= 3 experiments) of MC38
cells stably expressing shC or shKras treated with bortezomib (d) or IMD-0354 (e) for 72 h. P, probability of no difference between cell lines by extra sum-
of-squares F test. f, g Bioluminescent detection of NF-κΒ activity in KrasMUT (f) and KrasWT (g) cells stably expressing pNGL and the indicated vectors
during 4-h incubation with PBS or 1 nM TNF or IL-1β (n= 3 experiments). h, i Data summary (h; n= 6 mice/group) and images (i) of C57BL/6mice at 0 and
4 h after intrapleural injection of MC38 or PANO2 cells stably expressing pNGL and the indicated vectors. j Il1r1 mRNA expression by qPCR of KrasMUT and
KrasWT cells stably expressing the indicated vectors. k Immunoblots of protein extracts of MC38 and PANO2 cells stably expressing the indicated vectors
for NF-κB members after 4-h incubation with PBS or 1 nM TNF or IL-1β (n= 3 experiments). l The above extracts were subjected to EMSA. Super-shift
EMSA was performed with the indicated antibodies. IgG antibody served as negative control. Data are presented as mean± s.d. P, probability of no
difference between cell lines by two-way ANOVA. Single, double, and triple asterisks (*, **, and ***): P< 0.05, P< 0.01, and P< 0.001, respectively, for
comparison with pC or shC (a, f, h, j) or with PBS (g) by Bonferroni post-tests
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it functions as an autocrine growth factor across tumor types. On
the contrary, IL-1α/β selectively fostered MPE competence of
KRAS-mutant carcinomas, in agreement with previous reports of
IL-1β-induced NF-κB activation independent from IKKβ55. Our
ﬁndings explain how the tumor microenvironment fuels tumor
NF-κΒ activity56 and link the pro-tumorigenic functions of IL-1β
with KRAS mutations, setting a rationale for genotype-stratiﬁed
future investigations on IL-1β functions and therapies in cancer.
Unbiased analyses identiﬁed cancer-elaborated CXCL1/PPBP,
potent myeloid cell chemoattractants that drive inﬂammation and
metastasis via CXCR1/CXCR2 on host cells57,58, as the tran-
scriptional targets of IL-1β-fostered KRAS-IKKα addiction.
Indeed, Cxcl1 expression was downregulated by Kras or Chuk
silencing and IL-1β induced Cxcl1 expression by two different
cancer cell lines and Ppbp by LLC cells (MC38 cells do not
express Ppbp25). Our experiments using CXCR1- and CXCR2-
deﬁcient mice support that pleural tumor cell-secreted CXCL1/
PPBP is cardinal for MPE and are in line with a previous study
demonstrating increased production of CXCL1 by tumor cells
during human MPE development that mobilizes regulatory
T cells59.
In addition to the mechanistic insights into host environment-
fostered co-option of IKKα activity by mutant KRAS, our data
bear therapeutic implications for KRAS inhibitors39. KRAS is
notoriously undruggable, and proteasome and IKKβ inhibitors
have yielded suboptimal results in mice and men with cancer.
Focusing on lung cancer, a tumor with high KRAS mutation
frequency60, bortezomib has shown poor efﬁcacy in clinical
trials61. In animal models of lung cancer, bortezomib and IKKβ
inhibitors caused resistance or paradoxical tumor promotion via
development of secondary mutations, NF-κB inhibition in mye-
loid cells, or enhanced IL-1β secretion by tumor-associated
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neutrophils through an unknown mechanism15,16,53. We show
how KRAS-mutant cancer cells utilize myeloid-IL-1β in order to
activate IKKα and alternative NF-κB signaling and to by-pass
IKKβ canonical NF-κB dependence. We provide proof-of-concept
data that KRAS-mutant cancer cells can be targeted by combined
inhibition of KRAS and HSP90/IKKα/IKKβ signaling, a strategy
that blocks IL-1β-inducible oncogenic NF-κB activation and
in vivo MPE development, a cancer phenotype that requires
mutant KRAS-potentiated, IL-1β-induced IKKα activity. These
results challenge the prevailing focus on IKKβ for the develop-
ment of anti-tumor drugs and establish IL-1β and IKKα as
important targets in KRAS-mutant tumors.
In conclusion, we show that KRAS-mutant cancer cells use host
IL-1β to sustain IKKα-mediated non-canonical NF-κB activity
responsible for MPE development and primary drug resistance.
We identify CXCL1/PPBP as effectors of MPE downstream of
KRAS/IKKα addiction. Finally, we provide proof-of-concept data
suggesting that KRAS/IKKα addiction may occur in human
cancers and may be targeted by combined KRAS/IKKα inhibition.
Methods
Study approval. All mouse experiments were prospectively approved by the
Veterinary Administration of Western Greece (approval # 276134/14873/2) and
were conducted according to Directive 2010/63/EU (http://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=celex%3A32010L0063).
Reagents. D-Luciferin was from Gold Biotechnology (St. Louis, MO); lentiviral
shRNA and puromycin from Santa Cruz (Dallas, TX); 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay and Hoechst 33528 from Sigma-
Aldrich (St. Louis, MO); mouse gene ST2.0 microarrays and relevant reagents from
Affymetrix (Santa Clara, CA); recombinant cytokines and growth factors from
Immunotools (Friesoythe, Germany); NF-κB-binding ELISA from Active Motif (La
Hulpe, Belgium); bortezomib, IMD-0354, 17-DMAG, and deltarasin from Sell-
eckchem (Houston, TX); G418 from Applichem (Darmstadt, Germany); IL-1β and
CXCL1 ELISA from Peprotech (London, UK); and primers from VBC Biotech
(Vienna, Austria). Primers, antibodies, and lentiviral shRNA pools are listed in
Supplementary Tables 6–8.
Cells. LLC, B16F10, PANO2, and A549 cells were from the National Cancer
Institute Tumor Repository (Frederick, MD); MC38 cells were a gift from Dr.
Barbara Fingleton (Vanderbilt University, Nashville, TN)34,35, and AE17 cells from
Dr. YC Gary Lee (University of Western Australia, Perth, Australia)11,25. All cell
lines were cultured at 37 °C in 5% CO2–95% air using Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 10% fetal bovine serum, 2 mM L-glutamine, 1 mM
pyruvate, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cell lines were tested
annually for identity by short tandem repeats and forMycoplasmaSpp. by PCR. For
in vivo injections, cells were harvested using trypsin, incubated with Trypan blue,
counted in a hemocytometer, and 95% viable cells were injected
intrapleurally8,11,34,35.
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Fig. 6 IKKα is required for mutant KRAS-induced malignant pleural effusion. a–cMalignant pleural disease induced by LLC cells (KrasG12C) stably expressing
pNGL NF-κΒ reporter and control shRNA (shC) or shRNA targeting IKKα (shChuk), ΙΚΚβ (shIkbkb), ΙΚΚε (shIkbke), or TBK1 (shTbk1) transcripts (n is given
in Table 3). Shown are Kaplan–Meier survival plot (a), data summaries of effusion volume and pleural ﬂuid cells (b), and representative images of effusions
(dashed lines) and pleural tumors (t) as well as bioluminescent images at day 13 after pleural injections of the indicated tumor cells (c). d–f Malignant
pleural disease induced by MC38 cells (KrasG13R) stably expressing pNGL NF-κΒ reporter and shC, shChuk, or shIkbkb (n is given in Supplementary Table 3).
Shown are immunoblots of cytoplasmic extracts (d), data summaries of effusion volume and pleural ﬂuid cells (e), and representative images of effusions
(dashed lines) and pleural tumors (t) as well as representative bioluminescent images at day 13 after pleural injections of the indicated tumor cells (f). g–i
Malignant pleural disease induced by PANO2 cells (KrasWT) stably expressing pNGL NF-κΒ reporter and control plasmid (shC) or plasmid encoding IKKα
(pChuk), ΙΚΚβ (pIkbkb), or mutant (pKrasG12C) transcripts (n is given in Supplementary Table 3). Shown are Kaplan–Meier survival plot (g), data summary
of effusion volume (h), and representative images of effusions (dashed lines) and pleural tumors (t), hearts (h), and lungs (l), as well as representative
bioluminescent images at day 14 after pleural injections of the indicated tumor cells (i). Data are presented as mean± s.d. P, probability of no difference
between cell lines by overall log-rank test (a, g) or one-way ANOVA (b, e, h). ns, single, double, and triple asterisks (*, **, and ***): P> 0.05, P< 0.05, P<
0.01, and P< 0.001, respectively, for the indicated comparisons with control cells by Bonferroni post-tests. Scale bars, 0.5 cm
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Mouse models and drug treatments. C57BL/6 (#000664), B6.129P2-
Cxcr1tm1Dgen/J (Cxcr1−/−; #00582036), B6.129 S2(C)-Cxcr2tm1Mwm/J (Cxcr2+/−;
#00684837), B6;129S-Tnftm1Gkl/J (Tnf−/−; #00300832) (Jackson Laboratory, Bar
Harbor, ME), and Il1btm1Yiw (Il1b−/−; MGI #215739631) mice were bred at the
Center for Animal Models of Disease of the University of Patras. Male and female
experimental mice and littermate controls were sex, weight (20–25 g), and age
(6–12 weeks) matched. For MPE induction, mice received 150,000 cancer cells in
100 μL PBS intrapleurally. Mice were observed continuously till recovery and daily
thereafter and were sacriﬁced when moribund (13–14 days post-tumor cells) for
survival and pleural ﬂuid analyses. Mice with pleural ﬂuid volume ≥100 μL were
judged to have a MPE and were subjected to pleural ﬂuid aspiration, whereas
animals with pleural ﬂuid volume <100 μL were judged not to have a MPE and
were subjected to pleural lavage. Injection, harvest, and sample handling are
described elsewhere8–11,34,35. Drug treatments were initiated 5 days post-tumor
cells and consisted of daily intraperitoneal injections of 100 μL PBS containing no
drug, deltarasin39, 17-DMAG28, or both at 15 mg/kg.
Constructs. pNGL, pΙκΒαDN, and pCAG.LUC (#74409) have been described
elsewhere8,25,33. Lentiviral shRNA pools (Santa Cruz) are described in Supple-
mentary Table 8. A pMIGR1-based (#27490) bicistronic retroviral expression
vector was generated by replacing eGFP sequences with puromycin resistance gene
(#58250). KrasG12C,Chuk, Ikbkb, Ikbke, and Tbk1 cDNAs were cloned via reverse
transcriptase-PCR (RT-PCR) from LLC or MC38 RNA using speciﬁc primers
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Fig. 7 Myeloid cell-derived IL-1β drives mutant KRAS-IKKα addiction in malignant pleural effusion. a Malignant pleural disease induced by LLC cells
(KrasG12C) stably expressing pNGL NF-κΒ reporter plasmid in wild-type C57BL/6 mice (black) and TNF (blue) and IL-1β (red)-deﬁcient mice (Tnf−/− and
Il1b−/−, respectively; both C57BL/6 background; n is given in Supplementary Table 3). Shown are data summaries of effusion volume, pleural ﬂuid cells, and
NF-κΒ-dependent thoracic bioluminescent signal. b–d Malignant pleural disease induced by MC38 cells (KrasG13R) stably expressing pNGL NF-κΒ reporter
plasmid in wild-type C57BL/6 (black), Tnf−/− (blue), and Il1b−/− (red) mice (all C57BL/6 background; n is given in Supplementary Table 3). Shown are
data summaries of effusion volume, pleural ﬂuid cells, and NF-κΒ-dependent thoracic bioluminescent signal (b), representative images of effusions
(dashed lines), pleural tumors (t), and lungs (l) (c), as well as representative bioluminescent images at day 13 after pleural injections of the indicated tumor
cells (d). e, fMalignant pleural disease induced by LLC cells in Il1b−/− mice (C57BL/6 background; n is given in Supplementary Table 3) that received total
body irradiation (1100 Rad), same-day bone marrow transplants (10 million cells) from C57BL/6 (black), Tnf−/− (blue), or Il1b−/− (red) donors, and
pleural tumor cells after 1 month. Shown are data summaries of effusion volume and pleural ﬂuid cells (e) and representative images of effusions (dashed
lines), pleural tumors (t), lungs (l), and hearts (h) (f). g IL-1β protein secretion by C57BL/6mouse bone marrow-isolated myeloid cells 24 h after treatment
with LLC supernatants; undifferentiated cells (day 0), neutrophils (day 2 after addition of 20 ng/ml G-CSF), and macrophages (day 6 after addition of 20
ng/ml M-CSF; n= 3 independent experiments). Data are presented as mean± s.d. P, probability of no difference by one-way ANOVA. ns, single, double,
and triple asterisks (*, **, and ***): P> 0.05, P< 0.05, P< 0.01, and P< 0.001, respectively, for the indicated comparisons by Bonferroni post-tests. Scale
bars, 1 cm (c, f) and 100 μM (g)
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Fig. 8 CXCL1/PPBP are the downstream effectors of KRAS/IL-1β/IKKα signaling in malignant pleural effusion. a–c LLC and MC38 cells were stably
transfected with shC or shKras or shChuk or were stimulated with 1 nM IL-1β for 4 h, and total cellular RNA was examined by Affymetrix mouse gene ST2.0
microarrays. a Venn diagram of analytic strategy employed: transcripts altered >1.3-fold in one direction by shKras and shChuk and in the other by IL-1β
were ﬁltered for each cell line and are given in Supplementary Tables S1–S2. These gene sets, coined KRAS/IL-1β/IKKα signatures, were crossexamined and
only Cxcl1 was common to both. b Unsupervised hierarchical clustering of LLC cell results by the 29-gene KRAS/IL-1β/IKKα signature accurately clustered
three control samples together, shKras and shChuk samples together, and IL-1β-stimulated cells apart. c Cxcl1 mRNA normalized expression levels by
microarray (n= 2 independent experiments). d Cxcl1 mRNA expression by qPCR relative to Gusb (n= 3 independent experiments). e CXCL1 protein
secretion by LLC cells stably expressing shC, shChuk, or shKras after 24 h of stimulation with PBS or 1 nM TNF or IL-1β (n= 3 independent experiments). f
Chromatin immunoprecipitation (ChIP) was performed in PBS- or IL-1β-treated LLC cells, followed by immunoprecipitation with the indicated antibodies.
The immunoprecipitates were then detected by qPCR. Data are shown as fold enrichment of Cxcl1 or Gusb promoter in each antibody immunoprecipitate
over control IgG immunoprecipitate. gMalignant pleural disease induced by LLC cells in C57BL/6, Cxcr+/−, and Cxcr2+/− mice (n is given in Supplementary
Table 3). Shown are data summaries of effusion volume and pleural ﬂuid cells, as well as representative images of effusions (dashed lines), pleural tumors
(t), lungs (l), and hearts (h). h Data summaries of C57BL/6, Cxcr1−/−, Cxcr2+/− and Ccr2−/− pleural neutrophils and monocytes, accompanied by
microphotographs. Data are presented as mean± s.d. P, probability of no difference by two-way (c–e) or one-way (f–h) ANOVA. ns, single, double, and
triple asterisks (** and ***): P> 0.05, P< 0.05, P< 0.01, and P< 0.001, respectively, for comparison with PBS (e) or indicated (g, h) by Bonferroni post-
tests. Scale bars 1 cm (g) and 200 μM (h)
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(Supplementary Table 6) and were subcloned into peGFP-C1 (Takara, Mountain
View, CA). eGFP, eGFP.KrasG12C, eGFP.Chuk, eGFP.Ikbkb, eGFP.Ikbke, and eGFP.
Tbk1 cDNAs were subcloned into the new retroviral expression vector (#58249,
#64372,# 87033, #58251, #87444, and #87443, respectively). Retroviral particles
were obtained by co-transfecting HEK293T cells with retroviral vectors, pMD2.G
(#12259), and pCMV-Gag-Pol (Cell Biolabs, San Diego, CA) at 1.5:1:1 stoichio-
metry using CaCl2/BES. After 2 days, culture media were collected and applied to
cancer cells. After 48 h, media were replaced by selection medium containing 2–10
μg/mL puromycin. Stable clones were selected and subcultured11. For stable
plasmid/shRNA transfection, 105 tumor cells in six-well culture vessels were
transfected with 5 μg DNA using Xfect (Takara), and clones were selected by G418
(400–800 μg/mL) or puromycin (2–10 μg/mL).
Cellular assays. In vitro cancer cell proliferation was determined using MTT
assay. Nuclear extracts were assayed for RelA, RelB, c-Rel, P50, and P52 DNA-
binding activity using a commercially available ELISA kit (Transam, Active Motif,
Belgium). All cellular experiments were independently repeated at least thrice.
Bioluminescence imaging. Living cells and mice were imaged 0, 4, 8, 24, and 48 h
after cellular treatments and 0 h, 4 h, and 12–14 days after pleural delivery of
pNGL-expressing cells on a Xenogen Lumina II (Perkin-Elmer, Waltham, MA)
after addition of 300 μg/mL D-luciferin to culture media or isoﬂurane anesthesia
and delivery of 1 mg intravenous D-luciferin to the retro-orbital veins8–11,16,25,34,35.
Data were analyzed using Living Image v.4.2 (Perkin-Elmer).
qPCR and microarray. RNA was isolated using Trizol (Invitrogen, Carlsbad, CA)
and RNAeasy (Qiagen, Hilden, Germany) was reverse transcribed using Super-
script III (Invitrogen), and RT-PCR or qPCR was performed using SYBR Green
Master Mix in a StepOnePlus (Applied Biosystems, Carlsbad, CA) and speciﬁc
primers (Supplementary Table 6). Ct values from triplicate qPCR reactions were
analyzed by the 2–ΔΔCT method62 relative to Gusb mRNA levels. For microarray,
RNA was extracted from triplicate cultures of 106 cells. Five micrograms pooled
total RNA were quality tested on an ABI 2000 (Agilent Technologies, Sta. Clara,
CA), labeled, and hybridized to GeneChip Mouse Gene 2.0 ST arrays (Affymetrix,
St. Clara, CA). For analysis of differential gene expression (ΔGE) and unsupervised
hierarchical clustering, Affymetrix Expression and Transcriptome Analysis Con-
soles were used.
Chromatin immunoprecipitation. LLC cells were treated with PBS or 1 nM IL-1β,
and 30 min later, cells were ﬁxed sequentially with 2 mM di(N-succinimidyl)
glutarate (Sigma) and 1% formaldehyde (Sigma) and quenched with 0.125 M
glycine, followed by lysis with 1% sodium dodecyl sulfate (SDS), 10 mM EDTA,
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Fig. 9 Combined targeting of mutant KRAS and IKKα abolishes IL-1β-induced NF-κΒ activation and malignant pleural effusion development. a, b
Bioluminescent detection of NF-κΒ reporter activity in LLC (a; C57BL/6 Lewis lung carcinoma, KrasG12C) and A549 (b; human lung adenocarcinoma,
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comparison with TNF or IL-1β by Bonferroni post-tests. c Malignant pleural disease induced by LLC cells in wild-type C57BL/6 mice treated with deltarasin
and/or 17-DMAG. Mice received pleural LLC cells, were allowed 5 days for pleural tumor development, and were randomized to daily intraperitoneal
treatments with saline (100 μL), deltarasin, 17-DMAG, or both (both at 15 mg/Kg in 100 μL saline; n is given in Supplementary Table 3). Shown are data
summaries of effusion volume and pleural ﬂuid cells and Kaplan–Meier survival plot, as well as representative images of effusions (dashed lines), pleural
tumors (t), lungs (l), and hearts (h). Data are presented as mean± s.d. P, probability of no difference by one-way ANOVA or log-rank test. ns, single,
double, and triple (*, **, and ***): P> 0.05, P< 0.05, P< 0.01, and P< 0.001, respectively, for the indicated comparisons by Bonferroni post-tests. Scale
bars, 1 cm
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and 50 mM Tris pH 8. Sonication was performed in a Bioruptor (Diagenode) for 40
cycles (30 s on/off) power settings high), using 3 × 106 cells; 20 μg of chromatin was
precipitated with 5 μg of RelA, RelB, IKKα, or IKKβ antibody or a mouse control
immunoglobulin G (IgG). Immunoprecipitates were retrieved with 50 μl of mag-
netic Dynabeads conjugated to protein G (Invitrogen) and subjected to quantitative
real-time PCR (Applied Biosystems StepOne), using the Kapa SYBR Fast qPCR Kit
(KapaBiosystems, KK4605) for ampliﬁcation of the Cxcl1 promoter or Gusb as
control. The sequences of the primers used for Cxcl1 promoter are: 5′-ATA-
CAGCAGGGTAGGGATGC, 3′-TTGCCAACTGTTTTTGTGG. The sequences of
the primers used for Gusb are: 5′-TTACTTTAAGACGCTGATCACC, 3′-
ACCTCCAAATGCCCATAGTC.
BM cell derivation and transfer. For adoptive BM replacement, Il1β−/− mice
(C57BL/6 background) received 10 million BM cells ﬂushed from the femurs and
tibias of C57BL/6, Tnf−/−, or Il1β−/− donors (C57BL/6 background) intravenously
12 h after total-body irradiation (1100 Rad)11,25,34,35. One mouse in each experi-
ment was not engrafted (sentinel) and was observed till moribund between days 5
and 15 post-irradiation. The mice were left to be engrafted for 1 month, when full
BM reconstitution is complete, before experimental induction of pleural carcino-
matosis via intrapleural injection of LLC cells. For BM cell retrieval, BM cells were
ﬂushed from C57BL/6 femurs and tibias using full DMEM and were simply cul-
tured in full culture media (the same used for cancer cell line cultures), supple-
mented with 20 ng/ml M-CSF or G-CSF in order for cells to differentiate to
monocytes or neutrophils, respectively. Supernatants and cytocentrifugal speci-
mens were obtained at day 0 for undifferentiated cells, day 2 for neutrophils, and at
day 6 for monocytes/macrophages.
Immunoblotting. Nuclear and cytoplasmic extracts were prepared using the NE-
PER Extraction Kit (Thermo, Waltham, MA), separated by 12% SDS poly-
acrylamide gel electrophoresis, and electroblotted to polyvinylidene diﬂuoride
membranes (Merck Millipore, Darmstadt, Germany). Membranes were probed
with speciﬁc antibodies (Supplementary Table 7) and were visualized by ﬁlm
exposure after incubation with enhanced chemiluminescence substrate (Merck
Millipore, Darmstadt, Germany).
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were prepared
using the NE-PER Extraction Kit. Proteins (10 μg) were incubated with NF-κB
biotin-labeled probe using a commercially available non-radioactive EMSA Kit
(Signosis Inc, Santa Clara, USA). DNA–protein complexes were electrophoresed in
a prerinsed 6.5% polyacrylamide gel, transferred to a positively charged nylon
membrane, and were visualized by ﬁlm exposure after incubation with enhanced
chemiluminescence substrate. For gel shift reactions, proteins were incubated with
the speciﬁc antibody for 1 h at 4 °C before probe incubation. The antibodies used
for observing the supershifted bands were RelA and RelB. IgG antibody served as
negative control for super-shift assays.
Immunoﬂuorescence. For immunoﬂuorescence, cells were ﬁxed in 4% paraf-
ormaldehyde overnight at 4 °C and were labeled with the indicated primary anti-
bodies (Supplementary Table 7) followed by incubation with ﬂuorescent secondary
antibodies (Invitrogen, Waltham, MA; Supplementary Table 7). Cells were then
counterstained with Hoechst 33258 (Sigma-Aldrich, St. Louis, MO) and mounted
with Mowiol 4-88 (Calbiochem, Gibbstown, NJ). For isotype control, the primary
antibody was omitted. Fluorescent microscopy was carried out on an AxioObser-
ver.D1 inverted microscope (Zeiss, Jena, Germany) connected to an AxioCam ERc
5 s camera (Zeiss), and digital images were processed with the Fiji academic
imaging freeware63.
Statistics. Sample size was calculated using G*power (http://www.gpower.hhu.de/)64
assuming α = 0.05, β = 0.05, and d = 1.5, tailored to detect 30% differences between
means with 20–30% SD spans, yielding n = 13/group. Animals were allocated to
groups by alternation (treatments or cells) or case–control-wise (transgenic
animals). Data acquisition was blinded on samples coded by non-blinded
investigators. No data were excluded. All data were examined for normality by
Kolmogorov–Smirnof test and were normally distributed. Values are given as
mean± SD. Sample size (n) refers to biological replicates. Differences in means
were examined by t-test and one-way or two-way ANOVA with Bonferroni post-
tests, in frequencies by Fischer’s exact or χ2 tests, and in Kaplan–Meier survival
estimates by log-rank test, as appropriate. P-values are two-tailed. P< 0.05 was
considered signiﬁcant. Analyses and plots were done on Prism v5.0 (GraphPad, La
Jolla, CA).
Data availability. All new plasmids have been deposited at the Addgene plasmid
repository (https://www.addgene.org/search/advanced/?q=stathopoulos) and their
IDs (#) are given in the text. Microarray data are available at the GEO (http://www.
ncbi.nlm.nih.gov/geo/; Accession IDs: GSE93369 and GSE93370). The authors
declare that all the other data supporting the ﬁndings of this study are available
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mutations were assessed for NF-κΒ activation at resting and stimulated conditions in vitro. a Data summary (n= 5 independent experiments) of DNA NF-
κB motif-binding activity of nuclear extracts by NF-κB ELISA relative to nuclear extracts of Raji leukemia cells. Note increased nuclear RelB and P52 binding
activity of KRASMUT compared with KRASWT cells. b, c Bioluminescent detection of NF-κΒ reporter activity in A549, NCI-H23, HT29, and SKMEL2 cells
stably expressing pNGL, as well as in SKMEL2 cells stably expressing pNGL and pKrasG12C (b; data summary of n= 5 independent experiments; c:
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